Cardioprotection: An essential component of the treatment of chronic renal failure patients;La cardioprotection: Une composante essentielle du traitement de l'insuffisance rénale chronique dès le stade prédialytique

Nephrologie

Volumn 24, Issue 2, 2003, Pages 79-88

  Jungers, Paul ^a   Oualim, Z ^a   Nguyen Khoa, T ^a   Massy, Z ^a   London, G ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Atherosclerosis; Cardioprotection; Chronic renal failure; Ischemic cardiopathy; Left ventricular hypertrophy; Predialysis phase

Indexed keywords

ATHEROSCLEROSIS; CARDIOMYOPATHY; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; PATIENT CARE; POPULATION RESEARCH; PREVALENCE; REVIEW; RISK FACTOR; UREMIA;

ANEMIA; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 0344838634     PISSN: 02504960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999; 14: 828-33.
2. Excerpts from United States Renal Data System Annual Data Report. Am J Kidney Dis 1999; 34(2 Suppl. 1): S1-176.
3. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United Stated Renal Data System. Am J Kidney Dis 1997; 30: S67-85.
4. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis 1994; 24: 622-9.
5. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-15.
6. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
7. Disease NKFTFoC. Controlling the epidemic of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (Suppl. 3): S1-199.
8. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
9. Ibels LS, Alfrey AC, Huffer WE, Craswell PW, Anderson JT, Weil R, 3rd. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-6.
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-92.
11. Shinzato T, Nakai S, Akiba T, Yamagami S, Yamazaki C, Kitaoka T, et al. Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1999; 55: 700-12.
12. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-85.
13. Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997; 40: 1307-12.
14. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, et al. Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 1997; 29: 214-22.
15. Jungers P, Choukroun G, Robino C, Taupin P, Labrunie M, Man NK, et al. Epidémiologie de l'insuffisance rénale terminale en Ile-de-France: étude coopérative prospective en 1998. Nephrologie 2000; 21: 239-46.
16. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-34.
17. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS. Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995; 47: 884-90.
18. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989; 36: 286-90.
19. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996; 11: 1277-85.
20. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805.
21. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 1999; 56: 324-32.
22. Jungers P, Nguyen-Khoa T, Massy ZA, Zingraff J, Labrunie M, Descamps-Latscha B, et al. Incidence of atherosclerotic arterial occlusive accidents in predialysis and dialysis patients: A multicentric study in the Ile-de-France district. Nephrol Dial Transprant 1999; 14: 898-902.
23. Jungers P, Massy ZA, Nguyen-Khoa T, Fumeron C, Labrunie M, Lacour B, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: A prospective study. Nephrol Dial Transplant 1997; 12: 2597-602.
24. Ifudu O, Dawood M, Homel P, Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 1996; 28: 841-5.
25. Jungers P, Zingraff J, Albouze G, Chauveau P, Page B, Hannedouche T, et al. Late referral to maintenance dialysis: Detrimental consequences. Nephrol Dial Transplant 1993; 8: 1089-93.
26. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis 1998; 31: 398-417.
27. Jungers P, Choukroun G, Robino C, Massy ZA, Taupin P, Labrunie M, et al. Epidemiology of end-stage renal disease in the Ile-de-France area: A prospective study in 1998. Nephrol Dial Transplant 2000; 15: 2000-6.
28. Jungers P, Massy ZA, Nguyen-Khoa T, Choukroun G, Robino C, Fakhouri F, et al. Longer duration of predialysis nephrological care is associated with improved long-term survival of dialysis patients. Nephrol Dial Transplant 2001 (sous presse).
29. Guerin A, Marchais S, Pannier B, London G. Anomalies cardiaques dans l'insuffisance rénale chronique. Presse Med 2000; 29: 274-80.
30. Jungers P, Nguyen-Khoa T, Joly D, Choukroun G, Witko-Sarsat V, Massy ZA. Complications liées à l'athérosclérose dans l'insuffisance rénale chronique: épidémiologie et facteurs prédictifs. Actual Nephrol Hop Necker 2000; 41: 1-34.
31. Amann K, Ritz E. Reduced cardiac ischaemia tolerance in uraemia - what is the role of structural abnormalities of the heart? Nephrol Dial Transplant 1996; 11: 1238-41.
32. London GM. Heterogeneity of left ventricular hypertrophy- does it have clinical implications? Nephrol Dial Transplant 1998; 13: 17-9.
33. London GM, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Adv Ren Replace Ther 1997; 4: 194-211.
34. Meeus F, Kourilsky O, Guerin AP, Gaudry C, Marchais SJ, London GM. Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int 2000; 58 (Suppl. 76): S140-7.
35. Marchais SJ, Guérin AP, Métivier F, London GM. Remodelage artériel et fonction cardiovasculaire chez l'insuffisant rénal chronique. Actual Nephrol Hop Necker 1997; 38: 17-36.
36. London GM, Drüeke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51: 1678-95.
37. Mailloux LU, Haley WE. Hypertension in the ESRD patient: Pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998; 32: 705-19.
38. Harnett JD, Kent GM, Barre PE, Taylor R, Parfrey PS. Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol 1994; 4: 1486-90.
39. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, et al. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-8.
40. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-34.
41. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, et al. Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: 1921-9.
42. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61.
43. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-54.
44. London GM, Fabiani F, Marchais SJ, de Vernejoul MC, Guerin AP, Safar ME, et al. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973-80.
45. Pickering TG, Herman L, Devereux RB, Sotelo JE, James GD, Sos TA, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: Treatment by angioplasty or surgical revascularisation. Lancet 1988; 2: 551-2.
46. Wilson PW, Hoeg JM, D'Agostino RB, Silbershatz H, Belanger AM, Poehlmann H, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997; 337: 516-22.
47. Perry RJ, Griffiths W, Dextraze P, Solomon RJ, Trebbin WM. Elevated nicotine levels in patients undergoing hemodialysis. A role in cardiovascular mortality and morbidity? Am J Med 1984; 76: 241-6.
48. Lacour B, Massy ZA, Jungers P, Drüeke T. Anomalies du métabolisme des lipoprotéines dans l'insuffisance rénale chronique Néphrologie 1993; 14: 75-90.
49. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 1996; 11: 63-9.
50. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889-98.
51. Kronenberg F. Homocysteine, lipoprotein(a) and fibrinogen: Metabolic risk factors for cardiovascular complications of chronic renal disease. Curr Opin Nephrol Hypertens 1998; 7: 271-8.
52. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-8.
53. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int Suppl 1993; 41: S72-7.
54. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-58.
55. Yeun JY, Kaysen GA. C-reactive protein, oxidative stress, homocysteine, and troponin as inflammatory and metabolic predictors of atherosclerosis in ESRD. Curr Opin Nephrol Hypertens 2000; 9: 621-30.
56. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, et al. Oxidative stress and haemodialysis: Role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335-40.
57. Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-13.
58. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524-32.
59. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
60. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, Drüeke T, Descamps-Latscha B. Produits de l'oxydation avancée des protéines: marqueurs du stress oxydant et médiateurs de l'inflammation dans l'urémie. Actual Nephrol Hop Necker 1998; 39: 255-70.
61. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 1996; 21: 845-53.
62. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-36.
63. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-76.
64. Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 1998; 32: 834-41.
65. Amann K, Schwarz U, Törnig J, Stein G, Ritz E. Anomalies cardiaques au cours de l'urémie chronique. Actual Nephrol Hop Necker 1997; 38: 1-15.
66. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-96.
67. Demuth K, Blacher J, Guerin AP, Benoit MO, Moatti N, Safar ME, et al. Endothelin and cardiovascular remodelling in end-stage renal disease. Nephrol Dial Transplant 1998; 13: 375-83.
68. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
69. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
70. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-21.
71. Rostand SG, Drüeke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-92.
72. Levey AS. Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start? Am J Kidney Dis 1998; 32 (5 Suppl. 3): S5-13.
73. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000; 35 (4 Suppl. 1): S117-31.
74. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Jr., Rovin BH. Renoprotection: One or many therapies? Kidney Int 2001; 59: 1211-26.
75. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330: 877-84.
76. Chantrel F, Bouiller M, Kolb I, Hannedouche T. Traitement antihypertenseur du diabète et de la néphropathie diabétique de type II. Néphrologie 2000; 21: 47-55.
77. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 1997; 30: 659-64.
78. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-4.
79. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-35.
80. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
81. European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant 2000; 15 (Suppl. 7): 1-85.
82. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-8.
83. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-6.
84. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-85.
85. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-12.
86. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188-98.
87. Jungers P, Joly D, Massy Z, Chauveau P, Nguyen AT, Aupetit J, et al. Sustained reduction of hyperhomocysteinaemia with folic acid supplementation in predialysis patients. Nephrol Dial Transplant 1999; 14: 2903-6.
88. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drüeke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56: 2292-6.
89. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-9.
90. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001; 37: 484-9.
91. Pereira BJ. Optimization of pre-ESRD care: The key to improved dialysis outcomes. Kidney Int 2000; 57: 351-65.
92. e éd. Paris: Flammarion Médecine-Sciences, 2001.